Intelligence Profile
Safety Profile
Safety Profile of IGF-1 (Mecasermin)
Known Side Effects
Hypoglycemia appears to be the most significant and well-documented adverse effect of mecasermin treatment. Data from the EU-IGFD Registry specifically examined the frequency and predictive factors of hypoglycemia in patients treated with recombinant human IGF-1, indicating this is a recognized and monitored safety concern requiring clinical attention.
Evidence limitations: While hypoglycemia is clearly documented as a concern, the provided evidence does not include comprehensive details about the full spectrum of other potential side effects, their frequencies, or severity profiles. Additional safety data would be needed for a complete assessment.
Contraindications and Precautions
The evidence provided does not contain specific information about absolute contraindications for mecasermin use. However, given the documented risk of hypoglycemia, careful monitoring would be essential in patients with diabetes or other conditions affecting glucose metabolism.
Drug Interactions
Evidence gap: The provided research does not include information about drug interactions with mecasermin. This represents a significant knowledge gap that would require additional clinical data to address properly.
Special Populations
Based on the available evidence, mecasermin has been studied in several specific populations:
- Pediatric patients with severe IGF-1 deficiency and growth failure
- Patients with Rett syndrome (though one study notes that trofinetide, not mecasermin, is described as "a pioneering treatment" for this condition)
- Premature infants (being investigated for bronchopulmonary dysplasia prevention)
- Patients with 22q13 deletion syndrome (Phelan-McDermid syndrome)
Evidence limitations: The safety profiles specific to these populations are not detailed in the provided abstracts. Additionally, safety data for pregnant or breastfeeding women, elderly patients, and those with hepatic or renal impairment are not available in the current evidence.
Clinical Monitoring Requirements
Given the documented hypoglycemia risk, blood glucose monitoring would be essential during mecasermin treatment, though specific monitoring protocols are not detailed in the available evidence.
This safety information is based on limited research abstracts and clinical trial listings. A complete safety assessment would require access to full study reports, prescribing information, and regulatory documentation. Patients should consult healthcare providers for comprehensive safety information and individualized risk assessment.